LB

LB PHARMACEUTICALS INC

Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.

LBRX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
575 MADISON AVENUE, 10022 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for neuropsychiatric diseases. The company's pipeline is centered on its lead product candidate, LB-102, an oral small molecule aimed at treating schizophrenia, bipolar depression, and other central nervous system (CNS) disorders. LB Pharmaceuticals is focused on leveraging the therapeutic potential of LB-102, which it believes could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all LB PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LB PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LB PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.